AU2002364750A8 - Use of digestive enzyme mixtures for treating pathological bacterial overgrowth of the small intestine of mammals and humans - Google Patents

Use of digestive enzyme mixtures for treating pathological bacterial overgrowth of the small intestine of mammals and humans

Info

Publication number
AU2002364750A8
AU2002364750A8 AU2002364750A AU2002364750A AU2002364750A8 AU 2002364750 A8 AU2002364750 A8 AU 2002364750A8 AU 2002364750 A AU2002364750 A AU 2002364750A AU 2002364750 A AU2002364750 A AU 2002364750A AU 2002364750 A8 AU2002364750 A8 AU 2002364750A8
Authority
AU
Australia
Prior art keywords
mammals
humans
small intestine
digestive enzyme
bacterial overgrowth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002364750A
Other versions
AU2002364750A1 (en
Inventor
Christian Mandischer
Peter-Colin Gregory
Josef Kamphues
Robert Tabeling
Daniela Heldt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Original Assignee
Solvay Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals GmbH filed Critical Solvay Pharmaceuticals GmbH
Publication of AU2002364750A8 publication Critical patent/AU2002364750A8/en
Publication of AU2002364750A1 publication Critical patent/AU2002364750A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2002364750A 2001-12-14 2002-12-12 Use of digestive enzyme mixtures for treating pathological bacterial overgrowth of the small intestine of mammals and humans Abandoned AU2002364750A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33943801P 2001-12-14 2001-12-14
US60/339,438 2001-12-14
PCT/EP2002/014148 WO2003051345A2 (en) 2001-12-14 2002-12-12 Use of digestive enzyme mixtures for treating pathological bacterial overgrowth of the small intestine of mammals and humans

Publications (2)

Publication Number Publication Date
AU2002364750A8 true AU2002364750A8 (en) 2003-06-30
AU2002364750A1 AU2002364750A1 (en) 2003-06-30

Family

ID=23329006

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002364750A Abandoned AU2002364750A1 (en) 2001-12-14 2002-12-12 Use of digestive enzyme mixtures for treating pathological bacterial overgrowth of the small intestine of mammals and humans

Country Status (2)

Country Link
AU (1) AU2002364750A1 (en)
WO (1) WO2003051345A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
ES2732453T3 (en) 2008-07-01 2019-11-22 Curemark Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
WO2010080835A1 (en) 2009-01-06 2010-07-15 Curemark Llc Compositions and methods for the treatment or the prevention oral infections by e. coli
AU2010203709B2 (en) 2009-01-06 2014-05-22 Galenagen, Llc Compositions and methods for the treatment or prevention of Staphylococcus Aureus infections and for the Eradication or reduction of Staphylococcus Aureus on surfaces
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
SE535296C2 (en) 2010-09-08 2012-06-19 Anara Ab Maturation of the gastrointestinal tract
DK2701733T3 (en) 2011-04-21 2019-05-27 Curemark Llc CONNECTIONS FOR TREATMENT OF NEUROPSYCIATRIC DISORDERS
MX363096B (en) * 2012-01-03 2019-03-08 Curemark Llc Methods of treating behavioral symptoms of neurological and mental disorders.
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2638088C3 (en) * 1976-08-24 1979-06-21 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Use of sugar whey powder
US4447412A (en) * 1983-02-01 1984-05-08 Bilton Gerald L Enzyme-containing digestive aid compostions
DE4332985A1 (en) * 1993-09-28 1995-03-30 Konrad Peter Maria Dr Sommer Pharmaceutical composition for the treatment of exocrine pancreas dysfunction
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US6632429B1 (en) * 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof

Also Published As

Publication number Publication date
WO2003051345A3 (en) 2003-07-31
WO2003051345A2 (en) 2003-06-26
AU2002364750A1 (en) 2003-06-30

Similar Documents

Publication Publication Date Title
AU2002364750A8 (en) Use of digestive enzyme mixtures for treating pathological bacterial overgrowth of the small intestine of mammals and humans
EP1385476A4 (en) Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
EP1429617A4 (en) Methods for sterilizing preparations of digestive enzymes
EP1931272A4 (en) Methods and systems for determining physiologic characteristics for treatment of the esophagus
AU2003299961A1 (en) Capsule and method for treating or diagnosing conditions or diseases of the intestinal tract
HUP0203523A3 (en) The use of bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of various illnesses
HUP0500560A3 (en) Mixtures of mushroom enzymes and the use thereof for treating maldigestion
IL187030A0 (en) Use of retigabine for the treatment of neuropathic pain
AU2002225219A1 (en) Diagnosis and treatment of multiple sclerosis
ZA200007641B (en) Treatment of airborne allergens.
GB9824436D0 (en) Methods of treatment
DK1239872T3 (en) Enzyme treatment for digestive tract infections
GB9814377D0 (en) Treatment of airborne microorganisms
AU2002226984A1 (en) Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon
AU4541101A (en) Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
AU2002240336A1 (en) Methods for the diagnosis and treatment of tumors employing the hepsin gene
AU2002217316A1 (en) Use of terpenes for the treatment of digestive tract infections
IL137429A0 (en) Methods and compsitions for treating diseases and conditions of the eye
AU2003268295A1 (en) "diagnosis and treatment of infertility"
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
AP2002002483A0 (en) Lactic acid bacteria for the treatment and/or prophylaxix of giardasis
GB9929497D0 (en) Improved amino acid mixtures for the treatment and/or management of certain diseases
GB2381272B (en) Diagnosis and treatment of atherosclerosis
EP1107778A4 (en) Treatment of disease states
EP1409734A4 (en) Diagnosis and treatment of cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase